differences in demographic and clinical characteristics between type 2 and type 1 AMI were found. Higher age, female sex, co-morbidities, impaired renal function, anemia, inflammation and smaller extent of myocardial necrosis predispose to diagnosis of type 2 AMI.
Introduction: Hypercholesterolemia is a major risk factor for ischemic heart disease. Less is known about the impact of cholesterol levels in the course of an acute coronary syndrome (ACS). The aim of this study was to compare the occurrence of in-hospital complications in ACS patients accordingly to admission lipid levels. Methods: Participants in a nation wide ACS registry who had a complete lipid profile in the first 24 hours after hospitalization were selected. Data on 1694 patients (65.8% of the total number of patients included on the registry) were analyzed. Patients were divided accordingly to LDL-cholesterol (LDL) and HDL-cholesterol (HDL) tertiles. LDL groups were T1 <98 mg/dl, T2: 98-128 mg/dl and T3 >128 mg/dl and HDL tertiles were T1 <35 mg/dl, T2: 35-42 mg/dl and T3 >42 mg/dl. The occurrence of in-hospital re-infarction, heart failure and death was compared according to LDL and HDL tertiles. Results: Patients with lower LDL levels were older (mean age 70.5 years in group T1, 65.1 years in group T2 and 60.9 years in group T3, p<0.001), more frequently diabetic (39.4%, 26.6% and 17.6%, p<0.001), less often admitted with STEMI (41.4%, 46.4% and 49.8%, p<0 .001) and underwent percutaneous coronary intervention (PCI) less frequently (60.6%, 65.6% and 73.9%, p<0.001). Prevalence of diabetes was higher in patients with lower HDL levels (33.1% in tertile T1, 26.3% in T2 and 24.5% in T3, p<0.01) . No association was found between reinfarction and LDL or HDL levels. Killip class >1 was more frequently found in patients with lower LDL (33.6% in T1, 23.4% in T2 and 19.5% in T3, p<0 .001); no differences were found between HDL groups. In-hospital mortality was significantly higher in patients with low LDL (4.5% in T1, 2.2% in T2 and 0.9% in T3, p<0.001) but no association was found with HDL levels (3.0%, 1.8% and 2.9%, p=0.35). After adjusting for age, systolic blood pressure, admission diagnosis, admission blood glucose, previous use of beta blockers and coronary angiogataphy during hospitalization, LDL levels remained significantly associated with in-hospital mortality (OR [T1]: 3.99, 95% CI 1. OR [T2] : 3.70, 95% CI 1.14-12.02). No association or interaction was found with previous use of statins. Conclusions: Low LDL levels were associated with increased in-hospital mortality in ACS patients. It seems thar high cholesterol levels could be marker of improved survival not only in chronic diseases, as heart failure, but also in ACS.
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The high event rate in patients with diabetes mellitus treated with PCI for acute coronary syndromes is observed in the subgroup of patients with impaired renal function MACCE (Death, non-fatal myocardial infarction, non-fatal stroke).
Conclusions:-The adverse outcome after PCI in patients with ACS and diabetes is mainly observed in patients with impaired renal function. Therefore an impaired renal function indicates advanced atherosclerosis and a higher mortality risk even more accurate than diabetes alone. Background: Although coronary artery calcium (CAC) score has high specificity for predicting subclinical coronary artery diasease (CAD), it lacks sensitivity. Therefore, we aimed to evaluate if the measurement of pericardial fat volume (PFv) by non-contrast computed tomography (CT) in combination with CAC score would improve discrimination of coronary atherosclerotic plaques. Methods: 132 consecutive patients with suspected CAD were addressed to perform 64-slice CT both without contrast for CAC score and coronary angiography. During CT we evaluated both CAC score and PFv (in mm 3 ); and during angiography we evaluated PFv and the presence of coronary stenosis higher than 30%. In addition, we measured visceral abdominal adipose tissue (VAT) by abdominal CT and calculated Framinghan Heart Risk (FHR) score. Results: We found a strong association between PFv measured by non-contrast CT and the presence of coronary plaques with multivariate odds of 5.24 (95% CI 1.2-22, p=0.026). On sensitivity (sn), specificity (sp) and negative predictive value (npv) analysis for discrimination of coronary plaques, CAC score<10 + PFv measured by non-contrast CT presented the best predictive capacity (sn=93.3%; sp=100%; npv=99%) in comparison to CAC score<10 + PFv by angiography (sn=92.0%; sp=100%; npv=97%) or CAC score<10 + VAT (sn=90.7%; sp=100%; npv=95%); or even CAC score = 0 alone (sn=80%; sp=98%; npv=93%) or CAC score<10 alone (sn=80%; sp=100%; npv=93%). Furthermore, while in the entire cohort CAC score alone was better than the combination of CAC and PFv, when considering only patients with CAC score < 10, CAC score alone attained an area under the curve (AUC) of 0.808 (0.64 -0.97; p=0.001) versus 0.853 (0.74 -0.97; p<0.001) in CAC plus PFv model. Consistently, adding PFv to FHR score was better both in the entire cohort and in patients with CAC score<10, but tended to be more accurate in lower risk patients. Conclusions: This is the first study to shown PFv evaluation by non-contrast CT in combination with CAC score improves risk prediction of subclinical coronary artery disease in comparison with CAC score alone, especially in lower risk patients, without additional costs and risks of contrast infusion of coronary angiography.
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Blockade of platelet alpha2B-adrenergic receptors in patients with coronary artery disease: a novel antiaggregant mechanism Purpose: Platelets play a vital role in hemostasis and thrombosis. Catecholamines have a profound effect on platelet aggregation and atherothrombosis but the exact mechanism involved is insufficiently understood. In this report, we demonstrate the existence and role of alpha2B-adrenergic receptors (α2B-ARs) in platelets from patients with Coronary Artery Disease (CAD) compared to normal individuals. Methods: Sixteen healthy individuals and 7 patients with CAD who were under dual antiplatelet therapy with clopidogrel 75mg and acetylsalicylic acid 100mg were included. Blood samples were obtained from which platelets were isolated. The presence of α2B-ARs in platelets was proven by Western blot analysis and real time PCR. In order to investigate their function, we performed light transmittance aggregometry by examining the inhibitory effects of specific α2B-AR antibodies. Results: Pretreatment of human platelets with agents that selectively block α2B-ARs showed a substantial inhibition in platelet aggregation that had been induced by adenosine diphosphate (ADP), by epinephrine and by arachidonic acid. The percent aggregation decreased from 81.5±1.7% to 35.8±5% for ADP with α2B-Abs, from 72.2±1.9% to 25.5±4.3% for epinephrine with α2B-Abs, and from 87±2.1% to 47.9±6.2% for arachidonic acid with α2B-Abs, p<0.05 for all. Patients with CAD showed a significantly reduced expression of the receptor in the platelets (149.6±100.8 in normals versus 32.1±17.7, p = 0.015). Notably, pretreatment with α2B -Abs resulted in a significant further reduction of platelet aggregation. The ADP-treated plasma showed a significant reduction in platelet aggregation after pre-treatment with α2B-Abs (42±5.8% for the control group versus 31.7±2.2% for the group with α2B-Abs pretreatment, p< 0.001). When arachidonic acid was used to induce aggregation, pre-treatment with α2B -Abs reduced platelet aggregation from 41.2±7.3% to 28.2±7.5%, p= 0.006). Similarly, the presence of α2B-Abs decreased platelet aggregation induced by epinephrine from 44.4±22.1% to 19.1±7.2% (p = 0.01). Conclusions: Our results reveal that contrary to previous knowledge, the α2B-AR subtype does exist in platelets and is an important regulator of aggregation. Inhibition of α2B-ARs in platelets may offer a novel therapeutic opportunity in the prevention of atherothrombotic events. Interestingly, even in patients with coronary artery disease who were receiving dual antiplatelet therapy with aspirin and clopidogrel, the inhibition of α2B-ARs had an additional antiaggregant effect.
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Serum sclerostin levels are independently associated with coronary artery calcium score and carotid artery atherosclerosis in maintenance hemodialysis patients Background: Sclerostin is a protein expressed by osteocytes that has been shown to be associated with renal osteodystrophy and aortic valve calcification in dialysis patients. The aim of this study was to examine the association of serum sclerostin levels, coronary artery calcification score (CACS) and carotid artery intima media thickness (CIMT) in maintenance hemodialysis patients. Material and methods: Seventy two patients (38 females and 34 males) were subjected to 64 slice coronary computed tomography to evaluate coronary artery calcification. Moreover, patients underwent B mode ultrasonography of common carotid artery for measuring CIMT and evaluating the presence of plaques. Serum sclerostin levels were measured by an ELISA (R&D Systems, Minneapolis, MN). Results: Mean serum sclerostin level was higher compared to healthy age and gender matched controls (1472±948 vs 120±62 pg/ml, p<0.0001). Correlations between CACS and serum sclerostin levels (r=0.394, p=0.004), albumin (r=-0.471, p=0.004) and age (r=0.390, p=0.006) were noted. A negative but insignificant correlation was obtained between serum 25-hydroxy D3 levels and CACS (r=-0.162, p=0.245). Multivariable adjusted regression analyses revealed that increased serum sclerostin concentrations were independently associated with increased CACS (21,8% increase per 1-SD increase in sclerostin concentration, P = 0.04). On the CIMT analysis, serum sclerostin levels were positively correlated with CIMT (r=0.439, p<0.0001) while serum 25-hydroxy D3 levels were negatively correlated (r=-0.368, p=0.002). Patients with plaques on carotid arteries had higher serum sclerostin levels compared to ones with no plaques (2287±1681 vs 1174±917 pg/ml; p=0.016). Multivariable-adjusted regression analyses (also corrected for serum 25-hydroxy D3 levels and calcitriol use) revealed that increased serum sclerostin concentrations were independently associated with increased CIMT (32% increase per 1-SD increase in sclerostin concentration, P = 0.04). Conclusions: In this work, fine independent associations of serum sclerostin levels with both CACS and RCIMT were noted. The pathophysiological impact of these results need further investigations.
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Clinical outcome in cardiorenal patients related to coronary computed tomography angiography and serum adrenomedullin Background: Adrenomedullin is present in numerous human body tissues and its powerful vasodilatatory activity is thought to play role in cardiovascular/renal homeostasis and possibly in atherosclerosis. We conducted a prospective 2-year study of one hundred twenty-three patients with chronic kidney disease (CKD). Clinical outcome was analyzed to coronary computed tomography angiography (CCTA) findings and serum adrenomedullin levels. Methods: We determined plasma mid-regional pro-adrenomedullin (MRproADM) levels using sandwich immunoassay in patients (pts) on stage 2 to 5 CKD (glomerular filtration rate -GFR < 90 ml/min/1.73 m 2 ). Coronary artery calcification (CAC) and noninvasive coronary angiograms were performed by 64-multidetector computed tomography (Siemens, Germany). The presence of stenosis ≥ 50% during CCTA was considered as significant. The degree of coronary artery calcification was assessed using the Agatston calcium score method. Results: We studied consecutive 123 pts with suspected coronary artery disease (mean age 62.5±10.7 years, 57.7% male, arterial hypertension 89.2%, type 2 diabetes 25.2%, 29.0% had a history of tobacco use and 38.2% were on regular haemodialysis-mean 51.7 months, ranging from 3 to 252 months). On CCTA, 76 pts (65.0%) had no coronary artery disease (CAD),in 29 pts (24.8%) one significant epicardial stenosis and in 12 (10.3%) multivessel disease were documented. The mean MR-proADM plasma levels and CAC score were 1.4 nmol/l and 472.8, respectively. MR-proADM correlated with CAC (r=0.20; p=0.02), GFR (r=-0.75; p<0.001), total cholesterol and LDL-cholesterol (r=-0.36; p=0.02 and r=-0.34; p= 0.001). During follow-up period (18.4±6.2 months) 7 cardiovascular deaths were occurred and 1 patient underwent percutaneous coronary intervention for unstable angina. The main characteristics in pts with cardiac events or eventfree survival were the following: serum MR-proADM (2.5 vs 1.3 nmol/l), CAC (663.7 vs 462.5). When we compared these variables to cardiac events only significant difference was documented in MR-proADM levels (p=0,04). Otherwise, areas under receiver operating characteristic curve (AUC) for prediction of cardiovascular mortality were 0.82 (95% CI 0.67-0.97), 0.75 (95% CI 0.50-0.99) and 0.64 (95% CI 0.29-0.99) for MR-proADM vs duration of hemodialysis and CAC. Conclusions: Coronary computed tomography angiography and serum adrenomedullin represent new alternative diagnostic tools for risk stratification in special group of cardiorenal patients. Purpose: Aortic wall tissue invasion (AWTI) to the ostium of left main coronary artery (CA) (LMCA) is frequently observed on CT, which sometimes might be non calcified plaques on LMCA and are ignored as their significance is unclear. To evaluate the significance of AWTI to the ostium of the LMCA on CT, we examined the relationship between AWTI and CA risk factors, coronary arteriosclerosis and stenosis on CT and conventional coronary angiogram (CAG). Methods: Data on 103 consecutive subjects (70 male, mean age 64 y) who underwent both enhanced 320-slice CT and CAG within 3 months of each other without clinical accidents were retrospectively reviewed. Calcium volume (CV) (mm 3 ), Agatson calcium score (ACS), and log (ACS+1) on CT were measured and >50% and >75% luminal stenosis on both CT and CAG were evaluated. Results: AWTI to the ostium of LMCA on CT was observed in 75 subjects (50 male, mean age 65 y) (Group 1) and not observed in 28 subjects (20 male, mean
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